Rapid breathing relief patients can feel in 2 weeks and sustained through 1 year1,2

Baseline Blood EOS ≥300 cells/μL - QUEST (Secondary Endpoint)

  • At Week 12 in patients with no biomarker requirement: 320 mL improvement from baseline in pre-bronchodilator FEV1 with
    DUPIXENT 200 mg + SOC (n=631) vs 180 mL with placebo + SOC (n=317) (LSM difference: 140 mL [95% CI: 80, 190 mL]) (QUEST, primary endpoint)1
  • At Week 52 in patients with EOS ≥300 cells/μL: 480 mL improvement from baseline in pre-bronchodilator FEV1 with DUPIXENT
    300 mg + SOC (n=277) vs 230 mL with placebo + SOC (n=142) (QUEST, secondary endpoint)1
  • In QUEST, a significant difference from placebo + SOC was not observed at 12 weeks in change in pre-bronchodilator FEV1 in patients with baseline blood EOS ≥150 to <300 cells/μL taking DUPIXENT 300 mg + SOC and in patients with baseline blood EOS <150 cells/μL taking DUPIXENT 200 mg or
    300 mg + SOC1

Change in lung function over ~3 years4-6,c,d

Patients rolled into TRAVERSE OLE from QUEST (ITT) (secondary endpoint)

Mean

absolute

pre-BD

FEV1 (mL)

  • 2150
  • 2100
  • 2050
  • 2000
  • 1950
  • 1900
  • 1850
  • 1800
  • 1750
  • WEEKS:
  • YEARS:
SWIPE TO SEE SUSTAINED
IMPROVEMENT
  • 0
  • 2
  • 4
  • 6
  • 8
  • 10
  • 12
  • 16
  • 20
  • 24
  • 28
  • 32
  • 36
  • 40
  • 44
  • 48
  • 0
  • 2
  • 4
  • 8
  • 12
  • 24
  • 48
  • 72
  • 84
  • 96
QUEST TRAVERSE
Year 1 Year 2 Year 3
310mL IMPROVEMENT
AT WEEK 96e
DUPIXENT 300 mg + SOC (n=447) Placebo + SOC

310 mL improvement in FEV1 at Week 96 in the DUPIXENT/DUPIXENT group (n=447) from baseline in the parent study of 1.78 L for patients enrolled from QUEST (secondary endpoint)6,7

330 mL improvement in FEV1 at Week 96 in the placebo/DUPIXENT group (n=219) from baseline in the parent study of 1.75 L for patients enrolled from QUEST4,5

There are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.

c1.78 L was the baseline FEV1 level from QUEST (n=633) compared with a placebo value of 1.75 L (n=321).4

dFEV1 was assessed in the exposed population (observed cases) using descriptive statistics. Week 0 (TRAVERSE) represents the start of the OLE, and Weeks refers to the time in OLE without regard to any time in any parent study.6

eImprovement in FEV1 at Week 96 (n=447) in the DUPIXENT/DUPIXENT group from baseline in the parent study of 1.78 L.

Results are descriptive.

BD, bronchodilator.

VIEW THE FULL LONG-TERM EFFICACY AND SAFETY DATA
QUEST

FeNO ≥25 ppba,b

450 mL IMPROVEMENT IN LUNG FUNCTION AT WEEK 12

from baseline in pre-bronchodilator FEV1 with DUPIXENT 300 mg + SOC (n=295) vs 210 mL with placebo + SOC (n=167) (LSM difference: 240 mL [95% CI: 160, 310 mL])1,3

  • 440 mL improvement in lung function at Week 12 from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg + SOC (n=288) vs 210 mL with placebo + SOC (n=157) (LSM difference: 230 mL [95% CI: 150, 310 mL])1,3

a Results are descriptive.

b The clinical interpretation of FeNO in asthma is not established and levels may be influenced by confounding factors.